Navigation Links
Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
Date:9/1/2011

ntral nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has nearly completed an FDA-approved Phase Ia safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depression, and anticipates initiating a Phase Ib trial in the fall. Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For more information, please go to www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional inf
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
2. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
3. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
4. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
5. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
6. Neuralstem Completes $5.25 Million Financing
7. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
8. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
10. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
11. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VANCOUVER , Dec. 22, 2014 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development of ... paper out of the University of Calgary in conjunction ... North Carolina, which further validates the company,s ongoing clinical ... the effects of pattern baldness. The paper ...
(Date:12/22/2014)... December 22, 2014 ITRA Global, one ... occupiers of commercial real estate, has further expanded its ... in Perth and Brisbane, Western Australia, reports Mylinda Vick, ... , ITRA Global / ACORPP (Australian Corporate Property ... consultancy company providing property services to a wide range ...
(Date:12/19/2014)... Naurex Inc., a biopharmaceutical company leveraging its ... the central nervous system, today announced that Norbert ... present at the 33 rd annual J.P. Morgan ... 3:00 p.m. PST on Tuesday, January 13, 2015, at ... Calif. About Naurex Inc. ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... pharmacies, has an expanded team of Regional Pharmaceutical ... for prescriber offices in their regions, with specific ... have a variety of Regional Pharmaceutical Care Liaisons ... in hepatitis C help prescribers understand all the ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... demonstrates ,Best buy in public health, LONDON, Oct. ... ten years since its initiation, the international,effort to eliminate ... world of one of its most debilitating diseases.,The study ... million,children from acquiring LF and stopped another 9.5 million ...
... Steven Nissen to Chair Steering Committee for Landmark ... CALGARY, Oct. 7 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix" or ... of the Steering Committee for the RVX-208 Phase ... This is a,study in Acute Coronary Syndrome patients ...
... BioEnergy International, LLC,(BioEnergy), a privately-held, biotech developer ... announces the,addition of Norman R. Augustine to ... Augustine has a record of distinguished leadership ... and government culminating in his role as,Chairman ...
Cached Biology Technology:LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease 2LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease 3LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease 4International Steering Committee for RVX-208 IVUS Trial Formed 2International Steering Committee for RVX-208 IVUS Trial Formed 3BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 2BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 3
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "iPhone 5S ... Technology Report" report to their offering. ... Following the acquisition of AuthenTec in July 2012, ... iPhone 5S. It is currently the only device ...
(Date:12/17/2014)... 2014 The Defense Logistics Agency is ... detect and prevent counterfeit microcircuits from entering into ... started performing an in-house microcircuit anti-counterfeit initiative dubbed ... of purchased microcircuits while increasing their reliability throughout ... will be conducted at DLA,s Electronics Product Test ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... The development and first use of a high-density SNP ... genetic markers capable of revealing new insights into how ... measures, according to findings published in the current edition ... snapshot of the Anopheles gambiae genome can ...
... wheezing is related to how he or she grew at ... University of Southampton. The new research, funded by ... and undertaken at Southampton General Hospital, reveals that fetuses which ... are likely to go on to develop allergies and asthma ...
... to stand out and attract mates, according to a new ... in Seville, Spain, and colleagues. Their research is the first ... the secretions of their uropygial gland for cosmetic reasons. The ... birds and is situated near the base of the tail. ...
Cached Biology News:Genetic markers offer new clues about how malaria mosquitoes evade eradication 2Genetic markers offer new clues about how malaria mosquitoes evade eradication 3Allergies and wheezing illnesses in childhood may be determined in the womb 2Beauty from the bottom up 2
... The expertise that made the original Gene Pulser ... system available has been applied in the Gene ... The modular design of the Gene Pulser II ... accessory that has the widest range of settings ...
... and supplies, for 10 chips, provides ... perform protein analysis with 10 chips ... Supplied are 3 x 520 microliters ... 60 microliters Pro260 ladder (10-260 kD), ...
... and reliable automation for today's drug ... laboratories. Staccato Mini-Workstations offer the minimal ... liquid handling and material management tasks. ... Caliper's time proven CLARA™ assay development ...
...
Biology Products: